The role of miRNAs in ovarian cancer pathogenesis and therapeutic resistance–a focus on signaling pathways interplay

A Ismail, AI Abulsoud, D Fathi, A Elshafei… - … -Research and Practice, 2022 - Elsevier
One of the most prevalent and lethal forms of gynecological cancer is ovarian cancer (OC),
which is often diagnosed in its latter, deadly stages. The OC's high mortality and …

[HTML][HTML] Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review

E Hulstaert, A Morlion, K Levanon, J Vandesompele… - Gynecologic …, 2021 - Elsevier
Ovarian cancer is often diagnosed in an advanced stage and is associated with a high
mortality rate. It is assumed that early detection of ovarian cancer could improve patient …

[HTML][HTML] Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer

W Wang, HA Jo, S Park, H Kim, SI Kim, Y Han, J Lee… - Cancer letters, 2022 - Elsevier
Ovarian cancer is mostly diagnosed at advantaged stages due to the lack of early diagnostic
biomarkers. The common metastasis pattern is characterized by peritoneal dissemination …

Geniposide protects PC12 cells from lipopolysaccharide-evoked inflammatory injury via up-regulation of miR-145-5p

S Ma, C Zhang, Z Zhang, Y Dai, R Gu… - Artificial cells …, 2019 - Taylor & Francis
Geniposide is an active ingredient with anti-apoptotic and anti-inflammatory properties. This
study was to examine the effects of geniposide on a cell model of spinal cord injury (SCI) …

miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway

H Wu, J Liu, Y Zhang, Q Li, Q Wang, Z Gu - Clinical and Translational …, 2021 - Springer
Purpose miR-22 plays a great role in inhibiting cell growth, metastasis and enhanced cell
apoptosis in several cancers. The purpose of this study was to investigate the functions of …

Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies

LA McAlarnen, P Gupta, R Singh, S Pradeep… - Molecular Therapy …, 2022 - cell.com
Ovarian cancer most commonly presents at an advanced stage where survival is
approximately 30% compared with> 80% if diagnosed and treated before disease spreads …

Non-coding RNAs as biomarkers of tumor progression and metastatic spread in epithelial ovarian cancer

K Seborova, R Vaclavikova, L Rob, P Soucek… - Cancers, 2021 - mdpi.com
Simple Summary Despite advances in cancer research in recent years, efficient predictive
biomarkers of tumor progression and metastatic spread for ovarian cancer are still missing …

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations

S Quesada, M Fabbro, J Solassol - Cancers, 2022 - mdpi.com
Simple Summary High-grade serous ovarian cancer (HGSOC) is the most frequent and
lethal form of ovarian cancer and is associated with homologous recombination deficiency …

MicroRNA as biomarker in ovarian cancer management: Advantages and challenges

V Kumar, S Gupta, K Varma, M Sachan - DNA and Cell Biology, 2020 - liebertpub.com
Ovarian cancer is the most prevalent gynecological malignancy affecting women throughout
the globe. Ovarian cancer has several subtypes, including epithelial ovarian cancer (EOC) …

Quercetin and MicroRNA interplay in apoptosis regulation in ovarian cancer

K Khan, Z Javed, H Sadia, J Sharifi-Rad… - Current …, 2021 - ingentaconnect.com
The multifaceted nature of ovarian cancer has severely hampered the development of
effective therapeutics over the years. The complicate nature of ovarian cancer makes it …